Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALEC 
Alector Inc (ALEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ALEC (1-star) is a SELL. SELL since 3 days. Profits (0.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.65
1 Year Target Price $4.65
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.73% | Avg. Invested days 18 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 149.99M USD | Price to earnings Ratio - | 1Y Target Price 4.65 |
Price to earnings Ratio - | 1Y Target Price 4.65 | ||
Volume (30-day avg) 9 | Beta 0.72 | 52 Weeks Range 0.87 - 6.78 | Updated Date 07/3/2025 |
52 Weeks Range 0.87 - 6.78 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -139.74% | Operating Margin (TTM) -1216.52% |
Management Effectiveness
Return on Assets (TTM) -17.22% | Return on Equity (TTM) -90.26% |
Valuation
Trailing PE - | Forward PE 526.32 | Enterprise Value -164014063 | Price to Sales(TTM) 1.7 |
Enterprise Value -164014063 | Price to Sales(TTM) 1.7 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA -8.4 | Shares Outstanding 99992600 | Shares Floating 73907530 |
Shares Outstanding 99992600 | Shares Floating 73907530 | ||
Percent Insiders 9.95 | Percent Institutions 80.82 |
Upturn AI SWOT
Alector Inc
Company Overview
History and Background
Alector Inc. was founded in 2013. It is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Alector's focus is on harnessing the power of the immune system to combat diseases like Alzheimer's and frontotemporal dementia (FTD).
Core Business Areas
- Immuno-Neurology Drug Development: Alector focuses on discovering and developing therapies that target immune cell dysfunction in the brain to treat neurodegenerative diseases.
Leadership and Structure
Alector Inc. has a management team led by a Chief Executive Officer (CEO) and other key executives overseeing various departments, including research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- AL001 (titration of a monoclonal antibody targeting Signal Regulatory Protein alpha (SIRPu03b1)): AL001 targets CD47 to treat frontotemporal dementia (FTD). In 2017, Alector entered into a global co-development and co-commercialization partnership with AbbVie, now Allergan, for AL001. There is no precise market share available, but it is in clinical trials and represents a significant opportunity. Competitors include companies targeting the same disease area with different therapeutic approaches, e.g., gene therapy or other antibody approaches for FTD. Allergan is a partner.
- AL101 (progranulin agonist): AL101 is a progranulin (PGRN) agonist also targeting FTD. There is no precise market share data publicly available. Competitors include those focusing on FTD treatments and other immuno-neurology companies. No partner is currently associated to this drug.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically targeting neurodegenerative diseases, is characterized by high unmet needs, significant research and development investment, and regulatory hurdles. The Alzheimer's and dementia market are expected to grow significantly due to the aging population.
Positioning
Alector is positioned as a leader in the emerging field of immuno-neurology, aiming to address neurodegenerative diseases by modulating the immune system. Its competitive advantage lies in its novel approach.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is estimated to be in the tens of billions of dollars, with Alzheimer's disease alone representing a significant portion. Alector, if successful with its pipeline, is positioned to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Novel immuno-neurology approach
- Strong pipeline of drug candidates
- Partnership with established pharmaceutical companies (e.g. Allergan)
- Experienced management team
Weaknesses
- High risk associated with clinical-stage drug development
- Dependence on clinical trial outcomes
- Limited revenue stream currently
- Reliance on partnerships for funding
Opportunities
- Expanding pipeline into other neurodegenerative diseases
- Potential for breakthrough therapies in areas with high unmet need
- Strategic collaborations with other biotech and pharmaceutical companies
- Advancements in diagnostics for neurodegenerative diseases to improve patient selection
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other companies developing therapies for neurodegenerative diseases
- Patent challenges
Competitors and Market Share
Key Competitors
- Biogen Inc. (BIIB)
- Eli Lilly and Company (LLY)
- Roche Holding AG (RHHBY)
Competitive Landscape
Alector faces competition from established pharmaceutical companies with broader portfolios and greater resources. Its advantage lies in its specialized focus on immuno-neurology.
Growth Trajectory and Initiatives
Historical Growth: Alector's growth is primarily driven by its clinical pipeline and partnerships.
Future Projections: Future growth depends on clinical trial success and potential FDA approval of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials and exploring new immuno-neurology targets.
Summary
Alector is a clinical-stage biotech company pioneering immuno-neurology. Its novel approach targeting the immune system to combat neurodegenerative diseases is promising. Clinical trial success is critical to its growth. It must manage competition and regulatory hurdles effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may not be precise. Financial data should be verified independently.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alector Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-02-07 | Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 175 | Website https://www.alector.com |
Full time employees 175 | Website https://www.alector.com | ||
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.